Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Masonic Cancer Center, University of Minnesota
ClinicalTrials.gov Identifier:
NCT00617188
First received: February 14, 2008
Last updated: November 6, 2012
Last verified: November 2012
  Purpose

RATIONALE: Estrogen can cause the growth of ovarian epithelial cancer cells. Hormone therapy using fulvestrant may fight ovarian cancer by blocking the use of estrogen by the tumor cells.

PURPOSE: This phase II trial is studying how well fulvestrant works in treating patients with recurrent ovarian epithelial cancer.


Condition Intervention Phase
Ovarian Cancer
Drug: Fulvestrant
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Trial of Fulvestrant in Treatment of Recurrent Ovarian Carcinoma

Resource links provided by NLM:


Further study details as provided by Masonic Cancer Center, University of Minnesota:

Primary Outcome Measures:
  • Patients' Overall 90-Day Clinical Response as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) [ Time Frame: Day 90 ] [ Designated as safety issue: Yes ]
    Best response recorded from the start of treatment until Day 90. Defined by the sum of the Complete Responses (CR), Partial Responses (PR) and Stable Disease (SD) in patients treated with fulvestrant. CR=disappearance of all lesions, PR=>or =30% decrease in sum of all target lesions, Progressive Disease (PD) =>or=20% increase in sum of all target or any new lesions, SD=not CR, PR or PD.


Secondary Outcome Measures:
  • Patients' Overall 90-Day Clinical Response as Measured by Modified Response Evaluation Criteria in Solid Tumors (Rustin) [ Time Frame: Day 90 ] [ Designated as safety issue: No ]
    Defined by the sum of Complete Responses (CR), Partial Responses (PR) and Stable Disease (SD) in patients treated with fulvestrant. CR=normalization of serum CA-125 level from 2 initially elevated samples, PR=>or=50% decrease in serum CA-125 level from 2 initially elevated samples, Progressive Disease (PD)=CA-125 two times the upper limit of normal on 2 occasions (if previously normalized) OR CA-125 two times nadir (lowest value) on 2 occasions if elevated at initiation of treatment, SD=not CR, PR or PD.

  • Median Number of Days to Treatment Termination [ Time Frame: Up to 373 Days ] [ Designated as safety issue: No ]
    Time is determined from first dose to termination due to all causes.

  • Mean Scores - Quality of Life Assessment [ Time Frame: Baseline, 3 Months Post Treatment, 6 Months Post Treatment ] [ Designated as safety issue: No ]
    Functional Assessment of Cancer Therapy-Ovarian Cancer (FACT-O)Version 1/23/07 - This is a relative quality of life assessment; 100 = Best, 0 = Worst. It was developed and validated with cancer patients and includes physical well being, social well being, emotional well being and relationship with doctor subscales and can be summed into one total quality of life score. It is a standardized scale which collects data (scores 1-4) from 47 questions. Answers are transformed into a number between 0-100. Mean was calculated by adding up the values of the scores and dividing by the number of scores.

  • Serum Skeletal-Specific Alkaline Phosphatase Concentration [ Time Frame: Baseline, 1 Month, 3 Months, 6 Months ] [ Designated as safety issue: No ]
    Median Bone mineral results - assessed by serum skeletal-specific alkaline phosphatase laboratory results collected from patients in study.

  • Urine N-telopeptide Concentration [ Time Frame: Baseline, 1 Month, 3 Months, 6 Months ] [ Designated as safety issue: No ]
    Median bone mineral results - assessed by serial urine N-telopeptide laboratory results collected from patients.


Enrollment: 26
Study Start Date: June 2007
Study Completion Date: July 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Fulvestrant
Fulvestrant 500 milligrams (mg) Day 1; 250 mg Day 1, 29 and every 28 days thereafter.
Drug: Fulvestrant
Fulvestrant, 500 milligrams (mg) intramuscularly (IM) on Day 1, 250 mg IM on Day 15, and 250 mg IM on Day 29 and every 28 days thereafter until either intolerance or disease progression.
Other Name: Faslodex

Detailed Description:

OBJECTIVES:

Primary

  • To determine the 90-day clinical benefit (defined as the sum of complete responses, partial responses, and stable disease) in patients with recurrent ovarian epithelial cancer treated with single agent fulvestrant.

Secondary

  • To establish the time to termination of treatment (due to all causes including progression and intolerance) for patients treated with this drug.
  • To describe the toxicities observed in patients treated with this drug.
  • To evaluate the quality of life of patients treated with this drug.
  • To determine the effect that prolonged estrogen receptor antagonism has on markers of bone mineral turnover.

OUTLINE: Patients receive fulvestrant intramuscularly on days 1 and 15 of course 1 and then on day 1 of all subsequent courses. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients in continued response at the end of 1 year may continue treatment at the discretion of the treating physician.

Urinary N-telopeptide and serum skeletal-specific alkaline phosphatase are assessed at baseline and at 1, 3, and 6 months during study to determine the influence of estrogen blockade on bone mineral turnover.

Quality of life is assessed at baseline and every 3 months during treatment, and at the end of treatment using The Functional Assessment of Cancer Therapy - Ovarian (FACT-O) cancer questionnaire.

After completion of study treatment, patients are followed at approximately 30 days.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed ovarian epithelial carcinoma

    • Recurrent or persistent disease

      • Must have received greater than or equal to (≥) 2 prior cytotoxic chemotherapy regimens, including ≥ 1 platinum-containing regimen
    • Disease not amenable to curative treatment with surgery and/or radiotherapy
  • Must have measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) and/or a serum cancer antigen 125 (CA-125) level that is rising and meets 1 of the following criteria:

    • Serum CA-125 level greater than (>) upper limit of normal (typically 35 μ/mL) on two evaluations at least 2 weeks apart
    • Serum CA-125 level less than (<) 35 μ/mL but has risen progressively > 200% over successive specimens ≥ 2 weeks apart
  • Estrogen receptor-positive tumor
  • Gynecologic Oncology Group (GOG) performance status 0-3
  • Platelet count ≥ 50 x 10^9/Liter
  • Serum creatinine less than or equal to (≤) 2.5 mg/deciliter
  • Bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • Serum glutamic oxaloacetic transaminase (SGOT) ≤ 3 times upper limit of normal (ULN)
  • alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 2.5 times ULN (≤ 5 times ULN in the presence of liver metastases)
  • Alkaline phosphatase ≤ 3 times ULN
  • Prothrombin time-International Normalized Ratio (INR) ≤ 1.6
  • Not pregnant or nursing
  • Negative pregnancy test
  • Must be sterile or fertile patients must use effective contraception (i.e., double method including ≥ 1 barrier, injectable, implantable, condoms plus spermicide)
  • Prior malignancy allowed provided the patient has been disease-free for ≥ 5 years

    • Patients with previously diagnosed basal cell skin cancer are eligible immediately after completing therapy
  • No history of bleeding (i.e., disseminated intravascular coagulation or clotting factor deficiency)
  • No documented sensitivity to active or inactive excipients of fulvestrant (i.e., castor oil or mannitol)
  • Recovered from the effects of prior surgery, radiotherapy, and/or chemoradiotherapy
  • At least 3 weeks since prior chemotherapy
  • At least 3 weeks since prior complete radiotherapy regimen alone or chemoradiotherapy

    • An incomplete radiotherapy regimen (< 500 Gray) is allowed within the 3-week time frame

Exclusion Criteria:

  • Concurrent hormone replacement therapy
  • Prior long-term anticoagulation therapy other than anti-platelet therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00617188

Locations
United States, Minnesota
Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, United States, 55455
Sponsors and Collaborators
Masonic Cancer Center, University of Minnesota
Investigators
Principal Investigator: Peter A. Argenta, MD Masonic Cancer Center, University of Minnesota
  More Information

Additional Information:
Publications:
Responsible Party: Masonic Cancer Center, University of Minnesota
ClinicalTrials.gov Identifier: NCT00617188     History of Changes
Other Study ID Numbers: CDR0000582821, UMN-2007LS003, UMN-WCC-49, UMN-0612M97626, IRUSFULV0062
Study First Received: February 14, 2008
Results First Received: June 12, 2009
Last Updated: November 6, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Masonic Cancer Center, University of Minnesota:
recurrent ovarian epithelial cancer

Additional relevant MeSH terms:
Ovarian Neoplasms
Adnexal Diseases
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Neoplasms
Neoplasms by Site
Ovarian Diseases
Urogenital Neoplasms
Estradiol
Fulvestrant
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Estrogen Antagonists
Estrogen Receptor Modulators
Estrogens
Hormone Antagonists
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on October 23, 2014